&nbsp;

DPM-OropharyngealPositiveTreatment.pdf

Jun 2025

Regimen

DURV(MNT)

Cancer Type:

Gynecologic,

Endometrial

Intent: Adjuvant, Curative, Palliative

Drugs Used:

durvalumab (Compassionate)

Quick Link(s):

Regimen Monograph

Jun 2025

Document

Depistage-du-cancer-colorectal-print.pdf

Jul 2025

Regimen

NIVL+IPIL

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab – Previously Untreated Unresectable or Advanced Hepatocellular Carcinoma

New Drug Funding Program

Nivolumab plus Ipilimumab – Previously Untreated Unresectable or Advanced Hepatocellular Carcinoma

Drugs Used:

nivolumab,

ipilimumab

Quick Link(s):

Regimen Monograph

Jan 2026

Regimen

NIVL(MNT)

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab – Previously Untreated Unresectable or Advanced Hepatocellular Carcinoma

Drugs Used:

nivolumab

Quick Link(s):

Regimen Monograph

Jan 2026

Regimen

DURV

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Adjuvant, Curative

Drugs Used:

durvalumab (Compassionate)

Quick Link(s):

Regimen Monograph

Sep 2025

Document

DataTablesErrata.xlsx

New

Nov 2025

Document

DataFigures-Erratta.xlsx

New

Nov 2025

Regimen

DCTN

Cancer Type:

Gynecologic,

Gestational Trophoblastic Disease

Intent: Curative

Drugs Used:

DACTINomycin

Quick Link(s):

Regimen Monograph

Dec 2025

Regimen

NIVL+IPIL

Cancer Type:

Gastrointestinal,

Colorectal

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - MSI-H/dMMR Locally Advanced Unresectable or Metastatic Colorectal Cancer

New Drug Funding Program

Nivolumab plus Ipilimumab - MSI-H/dMMR Locally Advanced Unresectable or Metastatic Colorectal Cancer

Drugs Used:

nivolumab,

ipilimumab